Agilent, 863973-909, ZORBAX StableBond 300 C3, 4.6 x 150 mm, 3.5 µm

ZORBAX StableBond 300 C3, 4.6 x 150 mm, 3.5 µm. A reversed-phase C3 HPLC column with fully porous ZORBAX particles. StableBond technology ensures stability at low pH.

Specifications:
Brand: ZORBAX 300SB-C3
Hardware: SS
Inner Diameter (ID): 4.6 mm
LC Platform: Stainless Steel
Length: 150 mm
Maximum Temperature: 80 °C
Part Number Application Domain: Biopharma
Part Number Application: Monoclonal Antibodies (mABs)PeptidesProteins
Particle Size: 3.5 µm
Particle Type: Fully Porous
Phase: 300SB-C3
Pore Size: 300 Å
Pressure Rating: 400 bar
Separation Mode: Reversed Phase
Shipping Solvent: Acetonitrile/Water
Technique: LCLC & LC/MS
UNSPSC Code: 41115709
pH Range: 1-8

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
Engineered for robust and reliable reversed-phase liquid chromatography, this column features a C3 bonded phase on a durable 300 angstrom pore silica, making it ideal for high-resolution separations of large biomolecules including peptides, proteins, and monoclonal antibodies. Its 4.6 mm internal diameter and 150 mm length provide ample resolving power and sample capacity, while the 3.5 micron particle size ensures superior efficiency and sharp peak profiles in bioseparations.

This column is optimized for both analytical and preparative workflows, from pharmaceutical discovery to biotherapeutic characterization, allowing accurate molecular weight analysis, peptide mapping, and impurity profiling. Its StableBond chemistry delivers long column lifetimes under low pH conditions, supporting consistent performance even with challenging mobile phases or gradients. Laboratories employing LC and LCMS systems will benefit from its compatibility with Agilent 1100 and 1200 Series, as well as InfinityLab and most major HPLC instruments.

For comprehensive protein analysis, it can be used alongside other ZORBAX columns featuring different bonded phases such as C8 or C18, for method optimization and selectivity adjustment. This makes it a valuable component in routine QC, R&D, and validation environments across biotechnology and pharmaceutical sectors.